Hemispherx Biopharma
Hemispherx Biopharma, Inc.
1617 JFK Boulevard Suite 660
Philadelphia, PA 19103
Phone: (215) 988-0080Website: https://aimimmuno.com
Latest news
- AIM ImmunoTech to Evaluate Ampligen in Clinical Study for the Treatment of Post-COVID Conditions
12 October 2022 - Hemispherx Biopharma Posts USAMRIID Ebola Study Concluding Ampligen Produced 100% Survival Rate in Rodents with 100% Mortality in Placebo
9 February 2015 - Hemispherx Announces Data Showing Inhibition of Ebola by Ampligen Enlarged by Howard University Research
9 December 2014 - Hemispherx Biopharma Receives Complete Response Letter From FDA on Ampligen New Drug Application for Chronic Fatigue Syndrome
5 February 2013 - FDA Advisory Committee Makes Recommendations on Ampligen for Chronic Fatigue Syndrome
27 December 2012 - Hemispherx Biopharma Announces FDA Confirms Advisory Committee Meeting on December 20, 2012
23 October 2012 - Hemispherx Biopharma Announces FDA Advisory Committee Will Review Ampligen for Chronic Fatigue Syndrome
24 September 2012 - FDA Accepts Complete Response Submission Regarding the Ampligen New Drug Application for Chronic Fatigue Syndrome
14 August 2012 - Hemispherx Biopharma Files Complete Response With the FDA Regarding Its Ampligen New Drug Application for Chronic Fatigue Syndrome
1 August 2012 - Hemispherx Biopharma Reaches Agreement With FDA on Specific Steps
to Achieve Complete NDA on Proposed CFS Treatment Ampligen
7 March 2008
Drugs Associated with Hemispherx Biopharma, Inc.
Hemispherx Biopharma, Inc. manufactures, markets and/or distributes 1 drug in the United States. Medications listed here may also be marketed under different names in different countries. Non-US country and region specific information is not available on this page.
Brand/Generic Name | Reviews | Rating |
---|---|---|
Alferon N
Generic name: interferon alfa-n3 Drug class: interferons |
||
For ratings, users were asked how effective they found the medicine while considering positive/adverse effects and ease of use (1 = not effective, 10 = most effective). |